Episode

IV Fosphenytoin for Acute Trigeminal Neuralgia Exacerbations

Podcast
Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology
Published
Jun 21, 2026
Duration seconds
1075
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/amer-ghavanini/episodes/IV-Fosphenytoin-for-Acute-Trigeminal-Neuralgia-Exacerbations-e3l3ea5
Audio
https://anchor.fm/s/ff5a3958/podcast/play/121796357/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-21%2F0a561b0c-5081-7d5f-c2b1-250fcfba2609.m4a
JSON
/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/iv-fosphenytoin-for-acute-trigeminal-neuralgia-exacerbations
Markdown
/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/iv-fosphenytoin-for-acute-trigeminal-neuralgia-exacerbations.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/iv-fosphenytoin-for-acute-trigeminal-neuralgia-exacerbations/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/iv-fosphenytoin-for-acute-trigeminal-neuralgia-exacerbations.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

This source describes a phase 3 clinical trial investigating the effectiveness of intravenous fosphenytoin for treating sudden, intense flare-ups of trigeminal neuralgia . While standard oral medications often fail to provide immediate relief for this severe facial pain, the study found that injectable therapy significantly reduced pain levels within two hours compared to a placebo. Researchers also noted a substantial decrease in the frequency of attacks over a 24-hour period among those receiving the active drug. The trial results indicate that the treatment was well-tolerated , with only mild side effects like sleepiness and nausea reported by participants. Ultimately, the authors conclude that this medication offers a promising emergency intervention for patients in crisis, though larger studies are suggested to confirm these preliminary findings. This research provides high-level evidence for a fast-acting alternative to surgery or insufficient oral drugs.